Ruckus claims that nearly 60% of its revenues comes from telecommunications carriers such as Deutsche Telekom, demonstrating the strong business model of turning your financial backers into paying customers.

The flotation of US-based liver drugs maker Intercept Pharmaceuticals, majority owned by Genextra, came in October.

Double chin removing healthcare company Kythera Biopharmaceuticals backed by Foley Ventures, the corporate venturing unit of law firm Foley & Lardner, floats on October 10.

Reed Elsevier Ventures owns 18.3%.

YY would have an initial market capitalisation of $2.9bn at $11.50 per share.

Shionogi owns 12.5% of Enanta before its initial public offering, while Abbott Labs has 8.38%.

WiFi equipment maker Ruckus Wireless has set an initial public offering range of $13 per share to $15 per share and expects to sell 8.4m shares of stock.

Wintech owned a 7.3% stake, or 1.5 million shares, ahead of the flotation, which went down to 4.8% post the IPO.

Regulus Therapeutics has raised $80.9m in total proceeds from its initial public offering, a private placement, and convertible note.